Income Statement
CANDEL THERAPEUTICS, INC.
CADL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | 0.13 | 0.13 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | 0.13 | 0.13 |
|
Operating Expenses
|
48.27 | 33.37 | 38.39 | 34.85 | 25.85 |
|
Research & Development
|
30.50 | 19.31 | 24.51 | 20.79 | 15.18 |
|
Selling, General & Administrative
|
17.77 | 14.06 | 13.89 | 14.06 | 10.67 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-48.27 | -33.37 | -38.39 | -34.72 | -25.73 |
|
Non-Operating Income
|
10.08 | -21.81 | 0.45 | 15.93 | -10.40 |
|
Interest Income
|
- | - | 2.08 | - | - |
|
Interest Expense
|
2.12 | 2.00 | 2.60 | 1.60 | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-38.18 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-38.18 | -55.18 | -37.94 | -18.79 | -36.12 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-48.27 | -33.37 | -38.39 | -33.94 | -25.49 |
|
Earnings Per Share (Basic)
|
-0.72 | -1.74 | -1.31 | -0.65 | - |
|
Diluted EPS
|
-0.72 | -1.74 | -1.31 | -0.65 | - |
|
Weighted Average Shares
|
52.96 | 31.68 | 28.94 | 28.82 | - |
|
Diluted Weighted Avg Shares
|
52.96 | 31.68 | 28.94 | 28.82 | - |
|
Comprehensive Income
|
- | - | - | - | -36.12 |